There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Day One Biopharmaceuticals Inc (DAWN) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.23, or -1.96%, to $11.49. The Day One Biopharmaceuticals Inc has recorded 28,514 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $11.72 and fluctuated between $12.01 as its day high and $11.44 as its day low. The current market capitalization of Day One Biopharmaceuticals Inc is $1.02B. A total of 0.64 million shares were traded on the day, compared to an average of 837.86K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DAWN has seen 0 BUY and 3 SELL insider trades, representing the acquisition of 0 and the disposition of 4,586 shares. Over the last 12 months, there were 24 BUYs and 37 SELLs from insiders. Insiders purchased 1,623,452 shares during that period but sold 1,630,962.
In the most recent transaction, AI Day1 LLC bought 111,387 shares of DAWN for 9.97 per share on Oct 20. After the transaction, the 10% Owner now owns 12,929,322 company shares. In a previous transaction on Oct 19, AI Day1 LLC bought 384,400 shares at 10.06 per share. DAWN shares that 10% Owner owns now total 12,817,935.
Among the insiders who bought shares, AI Day1 LLC acquired of 979,667 shares on Oct 18 at a per-share price of $10.21. This resulted in the 10% Owner holding 12,433,535 shares of DAWN after the transaction. In another insider transaction, Bender Jeremy sold 2,996 shares at $13.86 per share on Aug 17. Company shares held by the Chief Executive Officer now total 704,224.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DAWN in the last 3 months, the mean price target is $37.78 with high estimates of $50.00 and low estimates of $10.00. In terms of 52-week highs and lows, DAWN has a high of $25.77 and a low of $9.67.
As of this writing, DAWN has an earnings estimate of -$0.59 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.52 per share and a lower estimate of -$0.64.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. DAWN’s latest balance sheet shows that the firm has $284.31M in Cash & Short Term Investments as of fiscal 2021. There were $220.00k in debt and $8.66M in liabilities at the time. Its Book Value Per Share was $4.48, while its Total Shareholder’s Equity was $281.15M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DAWN is Buy with a score of 4.40.